Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Respiratory Microbiota | Research

Lactobacillus casei combined with Lactobacillus reuteri alleviate pancreatic cancer by inhibiting TLR4 to promote macrophage M1 polarization and regulate gut microbial homeostasis

Authors: Zemin Zhu, Bo Yi, Zikai Tang, Xun Chen, Ming Li, Tao Xu, Zhijian Zhao, Caixi Tang

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

Pancreatic cancer is a highly lethal disease with no effective treatments. Lactobacillus casei (L. casei) and Lactobacillus reuteri (L. reuteri) exhibited therapeutic effects on several cancers, but their roles in pancreatic cancer are unknown. This study aims to explore how L. casei & L. reuteri influence pancreatic cancer and the underlying mechanisms.

Methods

Pancreatic cancer cells were treated with L. casei & L. reuteri and co-cultured with macrophages in a transwell system in vitro. Pancreatic cancer xenograft model was established and L. casei & L. reuteri was used to treat mice in vivo. MTT, CCK-8 assay or immunohistochemical staining were used to determine the proliferation of pancreatic cancer cells or tumor tissues. Transwell assay was applied to test the migration and invasion of pancreatic cells. RT-qPCR was utilized to assess TLR4 and MyD88 expressions in pancreatic cells or tumor tissues. WB, immunofluorescence staining, or flow cytometry was used to evaluate the M1/M2 polarization of macrophages. Besides, the composition of gut microbiota of tumor-bearing mice was determined by 16 S rRNA sequencing, and ultra-high performance liquid chromatography-mass spectrometry (UPLC-MS) untargeted metabolomics was used to evaluate the metabolic profiles of feces.

Results

L. casei & L. reuteri inhibited the proliferation, migration, invasion of pancreatic cancer cells and pancreatic cancer cell-induced M2 polarization of macrophages by suppressing TLR4. Meanwhile, L. casei & L. reuteri repressed pancreatic cancer growth and promoted M1 macrophage polarization. Besides, L. casei & L. reuteri reduced fecal Alloprevotella and increased fecal azelate and glutamate in nude mice, while TLR4 inhibitor TAK-242 increased Clostridia UCG-014, azelate, uridine, methionine sulfoxide, oxypurinol, and decreased glyceryl monoester in the feces of pancreatic tumor-bearing mice. Fecal oxypurinol and glyceryl monoester levels were positively or negatively associated with gut Clostridia UCG-014 abundance, respectively.

Conclusion

L. casei & L. reuteri alleviate pancreatic cancer by inhibiting TLR4 to promote macrophage M1 polarization and regulate gut microbial homeostasis.
Appendix
Available only for authorised users
Literature
1.
Collaborators GBDPC. The global, regional, and national burden of Pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the global burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2019;4(12):934–47.CrossRef
2.
Neoptolemos JP, et al. Therapeutic developments in Pancreatic cancer: current and future perspectives. Nat Rev Gastroenterol Hepatol. 2018;15(6):333–48.PubMedCrossRef
3.
4.
5.
Huang X, et al. Regulation of Tumor microenvironment for Pancreatic cancer therapy. Biomaterials. 2021;270:120680.PubMedCrossRef
6.
Farajzadeh Valilou S, et al. The role of inflammatory cytokines and Tumor associated macrophages (TAMs) in microenvironment of Pancreatic cancer. Cytokine Growth Factor Rev. 2018;39:46–61.PubMedCrossRef
7.
Yang J, et al. Macrophages in Pancreatic cancer: an immunometabolic perspective. Cancer Lett. 2021;498:188–200.PubMedCrossRef
8.
Hu H, et al. The M2 phenotype of tumor-associated macrophages in the stroma confers a poor prognosis in Pancreatic cancer. Tumour Biol. 2016;37(7):8657–64.PubMedCrossRef
9.
Laursen MF, Bahl MI, Licht TR. Settlers of our inner surface - factors shaping the gut microbiota from birth to toddlerhood. FEMS Microbiol Rev, 2021. 45(4).
10.
Cheng WY, Wu CY, Yu J. The role of gut microbiota in cancer treatment: friend or foe? Gut. 2020;69(10):1867–76.PubMedCrossRef
11.
Mendez R, et al. Microbial dysbiosis and polyamine metabolism as predictive markers for early detection of Pancreatic cancer. Carcinogenesis. 2020;41(5):561–70.PubMedCrossRef
12.
13.
Leal-Lopes C et al. Roles of Commensal Microbiota in Pancreas Homeostasis and Pancreatic Pathologies J Diabetes Res, 2015. 2015: p. 284680.
14.
15.
Panebianco C et al. Engineered resistant-starch (ERS) Diet shapes Colon Microbiota Profile in parallel with the retardation of Tumor Growth in In Vitro and in vivo Pancreatic Cancer models. Nutrients, 2017. 9(4).
16.
Sethi V, et al. Gut microbiota promotes Tumor Growth in mice by modulating Immune Response. Gastroenterology. 2018;155(1):33–37e6.PubMedCrossRef
17.
Dong J, et al. Bidirectional and dynamic interaction between the microbiota and therapeutic resistance in Pancreatic cancer. Biochim Biophys Acta Rev Cancer. 2021;1875(1):188484.PubMedCrossRef
18.
19.
20.
Legesse Bedada T, et al. Probiotics for cancer alternative prevention and treatment. Biomed Pharmacother. 2020;129:110409.PubMedCrossRef
21.
Zhu H, et al. The probiotic L. Casei Zhang slows the progression of acute and chronic Kidney Disease. Cell Metab. 2021;33(10):1926–42. e8.PubMedCrossRef
22.
Pan H, et al. A single bacterium restores the microbiome dysbiosis to protect bones from destruction in a rat model of rheumatoid arthritis. Microbiome. 2019;7(1):107.PubMedPubMedCentralCrossRef
23.
Kolodziej M, Szajewska H. Lactobacillus reuteri DSM 17938 in the prevention of antibiotic-associated Diarrhoea in children: a randomized clinical trial. Clin Microbiol Infect. 2019;25(6):699–704.PubMedCrossRef
24.
Nilsson AG, et al. Lactobacillus reuteri reduces bone loss in older women with low bone mineral density: a randomized, placebo-controlled, double-blind, clinical trial. J Intern Med. 2018;284(3):307–17.PubMedCrossRef
25.
Hu C et al. Gut microbiota-derived short-chain fatty acids regulate group 3 innate lymphoid cells in HCC Hepatology, 2022.
26.
27.
Bell HN, et al. Reuterin in the healthy gut microbiome suppresses Colorectal cancer growth through altering redox balance. Cancer Cell. 2022;40(2):185–200e6.PubMedCrossRef
28.
Samanta S. Potential impacts of Prebiotics and Probiotics on Cancer Prevention. Anticancer Agents Med Chem. 2022;22(4):605–28.PubMedCrossRef
29.
Riaz Rajoka MS, et al. Anticancer potential against cervix cancer (HeLa) cell line of probiotic Lactobacillus casei and Lactobacillus paracasei strains isolated from human breast milk. Food Funct. 2018;9(5):2705–15.PubMedCrossRef
30.
Rasouli BS, et al. In vitro activity of probiotic Lactobacillus reuteri against gastric cancer progression by downregulation of urokinase plasminogen activator/urokinase plasminogen activator receptor gene expression. J Cancer Res Ther. 2017;13(2):246–51.PubMedCrossRef
31.
32.
Chen SM, et al. The synergistic Tumor growth-inhibitory effect of probiotic Lactobacillus on transgenic mouse model of Pancreatic cancer treated with gemcitabine. Sci Rep. 2020;10(1):20319.PubMedPubMedCentralCrossRef
33.
Lupi LA, et al. The role of toll-like receptor 4 signaling pathway in ovarian, cervical, and endometrial cancers. Life Sci. 2020;247:117435.PubMedCrossRef
34.
Chen CY, Kao CL, Liu CM. The Cancer Prevention, anti-inflammatory and Anti-oxidation of Bioactive Phytochemicals Targeting the TLR4 Signaling Pathway. Int J Mol Sci, 2018. 19(9).
35.
Grimmig T et al. Toll Like Receptor 2, 4, and 9 Signaling Promotes Autoregulative Tumor Cell Growth and VEGF/PDGF Expression in Human Pancreatic Cancer Int J Mol Sci, 2016. 17(12).
36.
Sun Y, et al. Toll-like receptor 4 promotes angiogenesis in Pancreatic cancer via PI3K/AKT signaling. Exp Cell Res. 2016;347(2):274–82.PubMedCrossRef
37.
Yin H, et al. Gut-derived lipopolysaccharide remodels tumoral microenvironment and synergizes with PD-L1 checkpoint blockade via TLR4/MyD88/AKT/NF-kappaB pathway in Pancreatic cancer. Cell Death Dis. 2021;12(11):1033.PubMedPubMedCentralCrossRef
38.
Topcu KSB, et al. Investigation of the effects of the toll-like receptor 4 pathway on immune checkpoint vista in Pancreatic cancer. Invest New Drugs. 2022;40(3):519–28.PubMedCrossRef
39.
Michaud D, et al. Cell receptor signaling and protein kinase D2 support Regulatory B cell function in Pancreatic Cancer. Front Immunol. 2021;12:745873.PubMedCrossRef
40.
Gao J, Liang Y, Wang L. Shap Polarization Tumor-Associated Macrophages Cancer Immunotherapy Front Immunol. 2022;13:888713.
41.
Wang X, et al. Hypoxic tumor-derived exosomal miR-301a mediates M2 macrophage polarization via PTEN/PI3Kgamma to promote Pancreatic Cancer Metastasis. Cancer Res. 2018;78(16):4586–98.PubMedCrossRef
42.
He Z et al. Exosome-derived FGD5-AS1 promotes tumor-associated macrophage M2 polarization-mediated Pancreatic cancer cell proliferation and Metastasis. Cancer Lett, 2022: p. 215751.
43.
Alexander AF, et al. Single-cell secretion analysis reveals a dual role for IL-10 in restraining and resolving the TLR4-induced inflammatory response. Cell Rep. 2021;36(12):109728.PubMedPubMedCentralCrossRef
44.
Adolph TE, et al. Pancreas-Microbiota Cross talk in Health and Disease. Annu Rev Nutr. 2019;39:249–66.PubMedCrossRef
45.
Zhang L, et al. The oral Microbiota May have influence on Oral Cancer. Front Cell Infect Microbiol. 2019;9:476.PubMedCrossRef
46.
Zeng B, et al. The Oral cancer microbiome contains Tumor space-specific and clinicopathology-specific bacteria. Front Cell Infect Microbiol. 2022;12:942328.PubMedPubMedCentralCrossRef
47.
48.
Wang C, et al. Saccharomyces boulardii alleviates ulcerative Colitis carcinogenesis in mice by reducing TNF-alpha and IL-6 levels and functions and by rebalancing intestinal microbiota. BMC Microbiol. 2019;19(1):246.PubMedPubMedCentralCrossRef
49.
Manosroi A, et al. Characteristics and anti-proliferative activity of azelaic acid and its derivatives entrapped in bilayer vesicles in cancer cell lines. J Drug Target. 2007;15(5):334–41.PubMedCrossRef
50.
51.
52.
Capurso G et al. Probiotics and severe acute pancreatitis J Clin Gastroenterol, 2008. 42 Suppl 3 Pt 1: p. S148-51.
Metadata
Title
Lactobacillus casei combined with Lactobacillus reuteri alleviate pancreatic cancer by inhibiting TLR4 to promote macrophage M1 polarization and regulate gut microbial homeostasis
Authors
Zemin Zhu
Bo Yi
Zikai Tang
Xun Chen
Ming Li
Tao Xu
Zhijian Zhao
Caixi Tang
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11557-z

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue

Research

MicroRNA-191 regulates oral squamous cell carcinoma cells growth by targeting PLCD1 via the Wnt/β-catenin signaling pathway

Research

Does resection after neoadjuvant chemotherapy of docetaxel, oxaliplatin, and S-1 (DOS regimen) benefit for gastric cancer patients with single non-curable factor? a multicenter, prospective cohort study (Neo-REGATTA)

Research

Time trends in survival and causes of death in multiple myeloma: a population-based study from Germany

Research

Analysis of cells of epithelial, connective tissue and immune differentiation in HPV-positive-, HPV-negative oropharyngeal carcinoma and normal oropharyngeal tissue by immunofluorescence multiplex image cytometry: a preliminary report

Research

Small molecule targeting of the p38/Mk2 stress signaling pathways to improve cancer treatment

Study Protocol

Towards patient-led follow-up after curative surgical resection of stage I, II and III colorectal cancer (DISTANCE-trial): a study protocol for a stepped-wedge cluster-randomised trial
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits